Abstract:This study presents a novel Magnetic Nanoparticle‐Assisted Genome Editing (MAGE) platform that improves the delivery and genome editing capabilities of CRISPR‐Cas9 for treating Rett syndrome. This method involves using magnetic nanoparticles to sort patient‐derived cells after non‐viral plasmid delivery, significantly enhancing gene‐repairing efficiency and biocompatibility. The MAGE platform shows promise for stem cell therapies and the treatment of genetic disorders. The CRISPR‐Cas9 technology has the potential to revolutionize the treatment of various diseases, including Rett syndrome, by enabling the correction of genes or mutations in human patient cells. However, several challenges need to be addressed before its widespread clinical application. These challenges include the low delivery efficiencies to target cells, the actual efficiency of the genome‐editing process, and the precision with which the CRISPR‐Cas system operates. Herein, the study presents a Magnetic Nanoparticle‐Assisted Genome Editing (MAGE) platform, which significantly improves the transfection efficiency, biocompatibility, and genome‐editing accuracy of CRISPR‐Cas9 technology. To demonstrate the feasibility of the developed technology, MAGE is applied to correct the mutated MeCP2 gene in induced pluripotent stem cell‐derived neural progenitor cells (iPSC‐NPCs) from a Rett syndrome patient. By combining magnetofection and magnetic‐activated cell sorting, MAGE achieves higher multi‐plasmid delivery (99.3%) and repairing efficiencies (42.95%) with significantly shorter incubation times than conventional transfection agents without size limitations on plasmids. The repaired iPSC‐NPCs showed similar characteristics as wild‐type neurons when they differentiated into neurons, further validating MAGE and its potential for future clinical applications. In short, the developed nanobio‐combined CRISPR‐Cas9 technology offers the potential for various clinical applications, particularly in stem cell therapies targeting different genetic diseases.

Cell-Type-Specific Gene Inactivation and in Situ Restoration Via Recombinase-Based Flipping of Targeted Genomic Region

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Manipulations of MeCP2 in Glutamatergic Neurons Highlight Their Contributions to Rett and Other Neurological Disorders.

Generation and characterization of a human neuronal in vitro model for Rett Syndrome using a direct reprogramming method

Counter-balancing X-linked hypofunction by hyperfunction ameliorates disease features in a model of Rett syndrome: implications for genetic therapies

CRISPR-Cas9-mediated Genome Editing in One Blastomere of Two-Cell Embryos Reveals a Novel Tet3 Function in Regulating Neocortical Development

Genome-Wide Analysis Reveals Methyl-Cpg-Binding Protein 2-Dependent Regulation Of Micrornas In A Mouse Model Of Rett Syndrome

Modeling Rett Syndrome Using TALEN-Edited MECP2 Mutant Cynomolgus Monkeys

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels

Targeted RNA editing in brainstem alleviates respiratory dysfunction in a mouse model of Rett syndrome

Site-blocking antisense oligonucleotides as a mechanism to fine-tune MeCP2 expression

CRISPR/Cas9 knock‐in toward creating a Rett syndrome cell model with a synonymous mutation in the MECP2 gene

CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using in Utero Electroporation-based Gene Transfer

Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels

A Powerful Transgenic Tool for Fate Mapping and Functional Analysis of Newly Generated Neurons

Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome

A Partial Loss of Function Allele of Methyl-Cpg-binding Protein 2 Predicts a Human Neurodevelopmental Syndrome.

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

The Efficacy of a Human-Ready mini MECP2 Gene Therapy in a Pre-Clinical Model of Rett Syndrome

Loss and Gain of MeCP2 Cause Similar Hippocampal Circuit Dysfunction That is Rescued by Deep Brain Stimulation in a Rett Syndrome Mouse Model.